✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyTHC Why This Matters Arizona’s lack of a legal THC impairment threshold creates evidentiary ambiguity...
The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyTHCSafetyResearch Why This Matters Roadside THC testing accuracy directly affects clinicians’ ability to counsel patients...
‘Green lab’ helps Oregon officers recognize marijuana-impaired driving | The Astorian
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicySafetyResearch Why This Matters Clinicians should understand that law enforcement now has standardized training to...
`Cannabinoid Clinical Trials: CBD Doping Risk in Athletes`
Clinical Takeaway Daily use of a broad-spectrum CBD supplement containing trace amounts of other cannabinoids can result in urine concentrations of WADA-prohibited substances, a risk that increases with exercise. Athletes using CBD...
`Cannabinoid Clinical Trials: CBD, WADA, and Urine Testing`
Clinical Takeaway Athletes using broad-spectrum CBD supplements risk testing positive for WADA-prohibited cannabinoids such as CBG and CBDV, even when the CBD itself is legal. This study found that 10 weeks of...
`Cannabinoid Clinical Trials: CBD and WADA Drug Testing`
Clinical Takeaway Daily use of a broad-spectrum CBD supplement containing trace amounts of other cannabinoids can result in urine concentrations of WADA-prohibited substances such as CBG and CBDV, potentially placing athletes at...